EU tightens pharmacovigilance

When a medicine is already on the market, Europe still watches it like a carmaker watches brake failures after a recall. The European Medicines Agency says this safety system exists because harmful drug reactions were estimated to cause about 197,000 deaths a year in the European Union before the 2012 overhaul. (ema.europa.eu) That safety system is called pharmacovigilance, and the basic job is simple: collect reports of side effects, compare patterns across countries, and decide whether a label, warning, or approval needs to change. The European Medicines Agency says the current legal framework for that system has been in place since July 2012, with detailed operating rules set out in Commission Implementing Regulation (European Union) No 520/2012. (ema.europa.eu) (eur-lex.europa.eu) The new move is not a brand-new law but an update to the rulebook people actually use day to day. The European Union published Commission Implementing Regulation (European Union) 2025/1466 on July 23, 2025, and the consolidated text of the old rulebook now shows the amended version applying from February 12, 2026. (eur-lex.europa.eu 1) (eur-lex.europa.eu 2) One change hits the file every drug company keeps as its master safety map. The new regulation says that file should record only significant deviations from pharmacovigilance procedures, plus their impact and how they were managed, instead of turning the file into a warehouse for every minor issue. (eur-lex.europa.eu) Another change goes straight at outsourcing. The new text says that if a marketing authorisation holder hands safety work to a contractor, the delegation arrangements, each party’s responsibilities, and the audit and inspection arrangements must be clearly documented, and third parties must agree to be audited on the company’s behalf and inspected by regulators. (eur-lex.europa.eu) The biggest operational shift is in EudraVigilance, the European Union’s central database for suspected side effects. The European Medicines Agency’s January 28, 2026 questions-and-answers document says a pilot that started on February 22, 2018 has ended, and all marketing authorisation holders with medicines authorised in the European Economic Area now have to monitor the data available to them in that database. (ema.europa.eu) That means companies can no longer treat EudraVigilance like a regulator-only radar screen unless they were on the old pilot list. The same European Medicines Agency document says database monitoring must now be used as an additional source of safety information to support company signal detection, which is the process of spotting an unusual pattern before it becomes a confirmed risk. (ema.europa.eu) This is why the story lands in operating manuals, not just legal teams. The amending regulation says companies are required to establish quality systems for pharmacovigilance activities, so any change in what must be documented, monitored, outsourced, or audited flows straight into standard operating procedures, vendor contracts, affiliate roles, and inspection prep. (eur-lex.europa.eu) There is also a timing wrinkle. The European Medicines Agency said on January 28, 2026 that an update to Good Pharmacovigilance Practices Module Nine, the guidance tied to signal management, was scheduled for the second quarter of 2026, so companies have had to implement the legal changes before all the supporting guidance is fully refreshed. (ema.europa.eu) So the European Union has moved from saying “here is the framework” to saying “show us the workflow.” From February 12, 2026, medicine makers in Europe are being judged less on whether they can quote the rule and more on whether their databases, contractors, files, and internal controls already behave like the rule is real. (eur-lex.europa.eu) (ema.europa.eu)